Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Patient-specific experimental vaccine to prevent recurrence of glioblastoma

Mary Lee's primary care physician is also a family friend. When he walked into the exam room in October 2006 with tears in his eyes, she knew something serious was wrong. But she was shocked to learn she had a brain tumor - and later found out it was the most aggressive malignant type, a glioblastoma multiforme.

14 Oct 2010

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

TrovaGene, Inc. a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled "Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

13 Oct 2010

Rutgers University receives NIH grant to increase reliability of prostate cancer imaging

The National Institutes of Health has awarded a $3.3 million grant to a research team that includes Rutgers University to increase the reliability of imaging prostate cancer.

11 Oct 2010

Prostate cancer updates

Scientists have found that genetic variations for an enzyme involved in cell energy metabolism may increase the risk of prostate cancer. This variation in genes may impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate cells' responses to hormones and other signals, according to the U.S. National Institute of Child Health and Human Development researchers and colleagues.

8 Oct 2010

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

At the annual meeting of the North-Central American Urological Association, Mark Stovsky, MD, Case Western Reserve University School of Medicine Case Medical Center, and principal investigator, presented positive data combining the AnalizaDx SIA technology with the Nanosphere Verisens ultra-sensitive PSA assay.

7 Oct 2010

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced the publication of new research in the Canadian Urological Association Journal (CUAJ) showing that large-scale deletions in mitochondrial DNA (mtDNA) can indicate cellular changes that are associated with the development of cancer.

5 Oct 2010

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

Tengion, Inc. presented new research data yesterday in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy (ISCT) in San Francisco. The presentation highlighted new results from Tengion's Neo-Kidney Augment development program demonstrating success with an autologous cellular therapy approach to kidney regeneration in a rodent model of obesity, diabetes and hypertension.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010

MicroRNAs assay may allow better targeted therapy for lung cancer patients

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

30 Sep 2010

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

Santarus, Inc. and Cosmo Pharmaceuticals S.p.A. today announced positive top-line results from the Phase III clinical study conducted in the U.S. and India to evaluate the safety and efficacy of budesonide MMX® for the induction of remission of mild or moderate active ulcerative colitis. The study results show that budesonide MMX 9 mg taken once daily met the primary endpoint of superiority to placebo.

30 Sep 2010

ACT updates myoblast program for heart failure treatment

Advanced Cell Technology, a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies.

30 Sep 2010

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

Circadian Technologies (ASX.CIR) has announced today that it has partnered with Cincinnati Children’s Hospital Medical Centre (CCHMC) to develop and market a blood test to diagnose LAM, a serious lung disease that strikes women, usually in their child bearing years.

29 Sep 2010

U-M experts clear confusion over mammography screening controversy

A year after a government panel revised its recommendations for breast cancer screening, many professional organizations have not followed suit.

29 Sep 2010

Circulating tumor cells may be promising alternative for tumor biopsies

Circulating tumor cells (CTCs) may be a promising alternative, noninvasive source of tumor materials for biomarker assessment, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

Study finds PEM scanners equivalent to breast MRI in detecting cancerous lesions

In a prospective study published in the European Journal of Nuclear Medicine and Molecular Imaging, researchers at Boca Raton Regional Hospital (Boca Raton, FL) showed that Positron Emission Mammography (PEM) and breast MRI had comparably high ability to detect cancerous lesions.

29 Sep 2010

New predictive test to identify aggressive prostate cancer

S. Mark Redwood, M.D., chief of the Department of Urology at Sinai Hospital, is using a state-of-the-art predictive prostate cancer test called Prostate Px+ to better understand the aggressiveness of each individual patient's cancer and how best to treat it.

29 Sep 2010

Researchers discover new diagnostic test for prostate cancer

Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy.

From Oxford Gene Technology 29 Sep 2010

New disposable, microfluidic PDMS device for identification of advanced breast cancer

A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.

29 Sep 2010

State Roundup: N.Y. small businesses protest health insurance premium hikes; Arizona Medicaid crisis; a new payment system for Massachusetts?

Massachusetts officials are reviving the state's ambitious plan to change how doctors and hospitals are paid, aiming to hand the Legislature a specific proposal by Jan. 1 to end disagreement over controlling health spending.

28 Sep 2010

Biopsy News and Research

Further Reading

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

Patient-specific experimental vaccine to prevent recurrence of glioblastoma

TrovaGene receives patent for diagnosis and monitoring of pathogenic infection

Rutgers University receives NIH grant to increase reliability of prostate cancer imaging

Prostate cancer updates

AnalizaDx SIA technology, Nanosphere Verisens assay effective for prostate cancer diagnosis

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Tengion presents Neo-Kidney Augment development program at ISCT Symposium

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

MicroRNAs assay may allow better targeted therapy for lung cancer patients

Santarus, Cosmo announce positive results from budesonide MMX Phase III study in ulcerative colitis

ACT updates myoblast program for heart failure treatment

Circadian partners with Cincinnati Children's Hospital to develop blood test diagnostic for LAM, a serious lung disease

U-M experts clear confusion over mammography screening controversy

Circulating tumor cells may be promising alternative for tumor biopsies

Study finds PEM scanners equivalent to breast MRI in detecting cancerous lesions

New predictive test to identify aggressive prostate cancer

Researchers discover new diagnostic test for prostate cancer

New disposable, microfluidic PDMS device for identification of advanced breast cancer

State Roundup: N.Y. small businesses protest health insurance premium hikes; Arizona Medicaid crisis; a new payment system for Massachusetts?

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News